| Symbol | CBDY |
|---|---|
| Name | TARGET GROUP INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | L8W 2E7 Canada ON 20 Hempstead Drive |
| Telephone | 1 905-541-3833 |
| Fax | — |
| — | |
| Website | http://www.targetgroupinc.ca |
| Incorporation | US |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | FRUCI & ASSOCIATES, P.S.; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001586554 |
| Description | The Company is enaged in the medicinal and recreational cannabis business in Canada and in the Unietd States in those states where cannabis has been legalized for medicinal and recreational use. The Companys SIC Code is 2833-Medicinal and Chemical Botantical Products. Additional info from OTC: |
New Form 10-Q - Target Group Inc. Filed: 2025-11-07 AccNo: 0001104659-25-108491 Size: 7 MB
Read moreNew Form 10-K - Target Group Inc. Filed: 2025-03-27 AccNo: 0001410578-25-000510 Size: 8 MB
Read moreActinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
Read morePink Current symbol attribute type Security_Name was changed. Previous value: -. New value: TARGET GROUP INC.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: TARGET GROUP INC.
Read moreActinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
Read more